Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.
Identifieur interne : 000F18 ( PubMed/Corpus ); précédent : 000F17; suivant : 000F19Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.
Auteurs : Frédéric Libert ; François Coudoré ; Damien Richard ; Franck Durif ; Alain EschalierSource :
- Journal of mass spectrometry : JMS [ 1076-5174 ] ; 2005.
English descriptors
- KwdEn :
- Apomorphine (analogs & derivatives), Apomorphine (analysis), Apomorphine (blood), Apomorphine (pharmacokinetics), Apomorphine (urine), Catechol O-Methyltransferase Inhibitors, Catechols (therapeutic use), Gas Chromatography-Mass Spectrometry (methods), Humans, Nitriles, Parkinson Disease (drug therapy), Reproducibility of Results.
- MESH :
- chemical , analogs & derivatives : Apomorphine.
- chemical , analysis : Apomorphine.
- chemical , blood : Apomorphine.
- chemical , pharmacokinetics : Apomorphine.
- chemical , therapeutic use : Catechols.
- chemical , urine : Apomorphine.
- chemical : Catechol O-Methyltransferase Inhibitors, Nitriles.
- drug therapy : Parkinson Disease.
- methods : Gas Chromatography-Mass Spectrometry.
- Humans, Reproducibility of Results.
Abstract
A method was developed and validated for the analysis of R(-)-apomorphine, (R-)-apocodeine and R(-)-norapomorphine in human plasma and urine with N-propylnorapomorphine as internal standard using gas chromatography/mass spectrometry (GC/MS) and single-ion monitoring after a single liquid-liquid extraction and silylation of compounds. The quantification limits were 1 ng/ml for apomorphine and apocodeine and 25 ng/ml for norapomorphine. Calibration curves were linear, within the range 1-100 ng/ml. Variation in intraday and interday precision was below 10%. This method was applied to study apomorphine bioavailability in nine patients with Parkinson's disease before and after coadministration of a catechol-O-methyl transferase inhibitor.
DOI: 10.1002/jms.939
PubMed: 16285020
Links to Exploration step
pubmed:16285020Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.</title><author><name sortKey="Libert, Frederic" sort="Libert, Frederic" uniqKey="Libert F" first="Frédéric" last="Libert">Frédéric Libert</name><affiliation><nlm:affiliation>Pharmacology and Toxicology Laboratory, CHU G. Montpied, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Coudore, Francois" sort="Coudore, Francois" uniqKey="Coudore F" first="François" last="Coudoré">François Coudoré</name></author><author><name sortKey="Richard, Damien" sort="Richard, Damien" uniqKey="Richard D" first="Damien" last="Richard">Damien Richard</name></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name></author><author><name sortKey="Eschalier, Alain" sort="Eschalier, Alain" uniqKey="Eschalier A" first="Alain" last="Eschalier">Alain Eschalier</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16285020</idno><idno type="pmid">16285020</idno><idno type="doi">10.1002/jms.939</idno><idno type="wicri:Area/PubMed/Corpus">000F18</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F18</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.</title><author><name sortKey="Libert, Frederic" sort="Libert, Frederic" uniqKey="Libert F" first="Frédéric" last="Libert">Frédéric Libert</name><affiliation><nlm:affiliation>Pharmacology and Toxicology Laboratory, CHU G. Montpied, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Coudore, Francois" sort="Coudore, Francois" uniqKey="Coudore F" first="François" last="Coudoré">François Coudoré</name></author><author><name sortKey="Richard, Damien" sort="Richard, Damien" uniqKey="Richard D" first="Damien" last="Richard">Damien Richard</name></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name></author><author><name sortKey="Eschalier, Alain" sort="Eschalier, Alain" uniqKey="Eschalier A" first="Alain" last="Eschalier">Alain Eschalier</name></author></analytic><series><title level="j">Journal of mass spectrometry : JMS</title><idno type="ISSN">1076-5174</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apomorphine (analogs & derivatives)</term><term>Apomorphine (analysis)</term><term>Apomorphine (blood)</term><term>Apomorphine (pharmacokinetics)</term><term>Apomorphine (urine)</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Catechols (therapeutic use)</term><term>Gas Chromatography-Mass Spectrometry (methods)</term><term>Humans</term><term>Nitriles</term><term>Parkinson Disease (drug therapy)</term><term>Reproducibility of Results</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Apomorphine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Apomorphine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Apomorphine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Apomorphine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Catechols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="urine" xml:lang="en"><term>Apomorphine</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Catechol O-Methyltransferase Inhibitors</term><term>Nitriles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Gas Chromatography-Mass Spectrometry</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Reproducibility of Results</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A method was developed and validated for the analysis of R(-)-apomorphine, (R-)-apocodeine and R(-)-norapomorphine in human plasma and urine with N-propylnorapomorphine as internal standard using gas chromatography/mass spectrometry (GC/MS) and single-ion monitoring after a single liquid-liquid extraction and silylation of compounds. The quantification limits were 1 ng/ml for apomorphine and apocodeine and 25 ng/ml for norapomorphine. Calibration curves were linear, within the range 1-100 ng/ml. Variation in intraday and interday precision was below 10%. This method was applied to study apomorphine bioavailability in nine patients with Parkinson's disease before and after coadministration of a catechol-O-methyl transferase inhibitor.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16285020</PMID><DateCreated><Year>2005</Year><Month>12</Month><Day>06</Day></DateCreated><DateCompleted><Year>2006</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1076-5174</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>12</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of mass spectrometry : JMS</Title><ISOAbbreviation>J Mass Spectrom</ISOAbbreviation></Journal><ArticleTitle>Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.</ArticleTitle><Pagination><MedlinePgn>1521-5</MedlinePgn></Pagination><Abstract><AbstractText>A method was developed and validated for the analysis of R(-)-apomorphine, (R-)-apocodeine and R(-)-norapomorphine in human plasma and urine with N-propylnorapomorphine as internal standard using gas chromatography/mass spectrometry (GC/MS) and single-ion monitoring after a single liquid-liquid extraction and silylation of compounds. The quantification limits were 1 ng/ml for apomorphine and apocodeine and 25 ng/ml for norapomorphine. Calibration curves were linear, within the range 1-100 ng/ml. Variation in intraday and interday precision was below 10%. This method was applied to study apomorphine bioavailability in nine patients with Parkinson's disease before and after coadministration of a catechol-O-methyl transferase inhibitor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Libert</LastName><ForeName>Frédéric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pharmacology and Toxicology Laboratory, CHU G. Montpied, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coudoré</LastName><ForeName>François</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Damien</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Durif</LastName><ForeName>Franck</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Eschalier</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Studies</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Mass Spectrom</MedlineTA><NlmUniqueID>9504818</NlmUniqueID><ISSNLinking>1076-5174</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065098">Catechol O-Methyltransferase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002396">Catechols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>478-76-2</RegistryNumber><NameOfSubstance UI="C008668">norapomorphine</NameOfSubstance></Chemical><Chemical><RegistryNumber>4975G9NM6T</RegistryNumber><NameOfSubstance UI="C071192">entacapone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical><Chemical><RegistryNumber>OBF8X37Y5W</RegistryNumber><NameOfSubstance UI="C006613">apocodeine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065098" MajorTopicYN="N">Catechol O-Methyltransferase Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002396" MajorTopicYN="N">Catechols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008401" MajorTopicYN="N">Gas Chromatography-Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16285020</ArticleId><ArticleId IdType="doi">10.1002/jms.939</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000F18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16285020
|texte= Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16285020" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |